 <!--program start-->
        <div class="col-md-12 mt-2">
            <div class="tab" role="tabpanel">
                <!-- Nav tabs -->
                <ul class="nav nav-tabs" role="tablist">
                    <li role="presentation" class="active"><a href="<?php echo base_url();?>program/day1" aria-controls="home" role="tab" data-toggle="tab">Day 1, Friday 19<sup>th</sup> April 2019</a></li>
                    <li role="presentation"><a href="<?php echo base_url();?>program/day2" aria-controls="profile" role="tab" data-toggle="tab">Day 2, Saturday 20<sup>th</sup> April 2019</a></li>
                     <li role="presentation"><a href="<?php echo base_url();?>program/day3" aria-controls="profile" role="tab" data-toggle="tab">Day 2, Sunday 21<sup>st</sup> April 2019</a></li>
                </ul>
                <!-- Tab panes -->
                <div class="tab-content tabs">
                    <div role="tabpanel" class="tab-pane  in active" id="Section1">
                      <!--session 1 start-->
                      <div class="section-tab">
                          <h3><span class="year">08.00 - 09.00</span> Registration</h3>
                        <h3><span class="year">09.00 - 09.49</span> Session 1 : Key Publications/Abstracts on Oral Cancers</h3>
                        <span class="time">09.00 - 09.07</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Obturators versus flaps after maxillary oncological ablation: A systematic review and best evidence synthesis</p>
                          <h6>Author : Yubin Cao</h6>
                          <h6>Citation : Oral Oncology July 2018Volume 82, Pages 152–161</h6>
                        </div>
                        <span class="time">09.07 - 09.14</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Treatment guidelines and patterns of care in oral cavity squamous cell carcinoma: Primary surgical resection vs. Nonsurgical treatment</p>
                          <h6>Author : Rance J.T. Fujiwara</h6>
                          <h6>Citation : Oral Oncol. 2017 Aug;71:129-137</h6>
                        </div>
                        <span class="time">09.14 - 09.21</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> The role of adjuvant treatment in early-stage oral cavity squamous cell carcinoma: An International collaborative study</p>
                          <h6>Author : Eran Fridman</h6>
                          <h6>Citation : Cancer. 2018 Jul 15;124(14):2948-2955</h6>
                        </div>
                        <span class="time">09.21- 09.28</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Original article: Metronomic chemotherapy in platinum-insensitive failures and/or early failures post multimodality management in oral cancers</p>
                          <h6>Author : Vijay M Patil</h6>
                          <h6>Citation : Indian Journal of Medical and Paediatric Oncology, Year 2015, Volume 36, Issue 3 [p. 161-165]</h6>
                        </div>
                        <span class="time">09.28 - 09.35</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Patterns of care in adjuvant therapy for resected oral cavity squamous cell cancer in elderly patients</p>
                          <h6>Author : Pollom EL</h6>
                          <h6>Citation : Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):758-766</h6>
                        </div>
                        <span class="time">09.35 - 09.42</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Impact of radical treatments on survival in locally advanced T4a and T4b buccal mucosa cancers: Selected surgically treated T4b cancers   have similar control rates as T4a</p>
                          <h6>Author : Manish D. Mair</h6>
                          <h6>Citation : Oral Oncology July 2018Volume 82, Pages 17–22</h6>
                        </div>
                        <span class="time">09.42 - 09.49</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Induction chemotherapy in technically unresectable locally advanced T4a oral cavity squamous cell cancers: Experience from a regional cancer center of South India</p>
                          <h6>Author : AH Rudresha</h6>
                          <h6>Citation : Indian Journal of Medical and Paediatric Oncology, Vol. 38, No. 4, October-December 2017, pp. 490-494</h6>
                        </div>
                          <h4><span class="year">09.49 - 10.19</span> Panel Discussion on Oral Cancers</h4>
                      </div>
                      <!--session 1 end-->
                      <!-- session 2 start-->
                      <div class="section-tab">
                        <h3><span class="year">10.19 - 11.24</span> Session 2 :  Key Publications/Abstracts on Oropharynx</h3>
                        <span class="time">10.19 - 10.26</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Treatment of early stage Supraglottic squamous cell carcinoma: metaanalysis comparing primary surgery versus primary radiotherapy</p>
                          <h6>Author : Krupal B. Patel</h6>
                          <h6>Citation : Journal of Otolaryngology - Head & Neck Surgery201847:19</h6>
                        </div>
                        <span class="time">10.26 - 10.33</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Oncological outcome following De-intensification of treatment for stage I and II HPV negative oropharyngeal cancers with Transoral Robotic Surgery (TORS): A prospective trial</p>
                          <h6>Author : Surender Dabas</h6>
                          <h6>Citation : Oral Oncology June 2017 Volume 69, Pages 80–83</h6>
                        </div>
                        <span class="time">10.33 - 10.40</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Transoral robotic surgery for management of cervical unknown primary squamous cell carcinoma: Updates on efficacy, surgical technique and margin status</p>
                          <h6>Author : Mathew Geltzeiler</h6>
                          <h6>Citation : Oral Oncology March 2017,Volume 66, Pages 9–13</h6>
                        </div>
                        <span class="time">10.40 - 10.47</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-Associated oropharyngeal squamous cell cancer</p>
                          <h6>Author : Jacqueline R. Kelly</h6>
                          <h6>Citation : ORAl Oncology April 2018Volume 79, Pages 64–70</h6>
                        </div>
                        <span class="time">10.47 - 10.54</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Concurrent Chemoradiotherapy (CCRT) versus induction docetaxel, cisplatin and 5-Fluorouracil (TPF) followed by CCRT in locally advanced hypopharyngeal and base of tongue cancer: A randomized Phase II study</p>
                          <h6>Author : S. H. Lim</h6>
                          <h6>Citation : Annals of Oncology 28 (Supplement 5): v372_v394, 2017</h6>
                        </div>
                          <h4><span class="year">10.54 - 11.24</span> Panel Discussion on Oropharynx Cancers</h4>
                          <h4><span class="year">11.24 - 11.40</span> Tea/Coffee Break</h4>
                      </div>
                      <!--session 2 end-->
                      <!-- session 3 start-->
                      <div class="section-tab">
                        <h3><span class="year">11.40 - 12.01</span>Session 3 : Key Publications/Abstracts on Nasopharyngeal Cancers</h3>
                        <span class="time">11.40 - 11.47</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative</p>
                          <h6>Author : Ward MC</h6>
                          <h6>Citation : Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):586-594</h6>
                        </div>
                        <span class="time">11.47- 11.54</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Epidemiology and outcomes of nasopharyngeal carcinoma: Experience from a regional cancer center in Southern India</p>
                          <h6>Author : Haleshappa RA</h6>
                          <h6>Citation : South Asian J Cancer. 2017 Jul-Sep;6(3):122-124</h6>
                        </div>
                        <span class="time">11.54 - 12.01</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II–IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial</p>
                          <h6>Author : Lin-Quan Tang</h6>
                          <h6>Citation : The lancet : Volume 19, No. 4, p461–473, April 2018</h6>
                        </div>
                          <h4><span class="year">12.01 - 12.31</span> Panel Discussion on Nasopharynageal Cancers</h4>
                          <h4><span class="year">12.31 - 13.11</span> Checkmate in reccurent/metastatic head and neck cancer </h4>
                          <h4><span class="year">13.11 - 14.00</span> Lunch </h4>
                      </div>
                      <!--session 3 end-->
                      <!-- session 4 start-->
                      <div class="section-tab">
                        <h3><span class="year">14.00 - 14.28</span>Session 4: Key Publications/Abstracts on special population(elderly/secondary)</h3>
                        <span class="time">14.00 - 14.07</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i>Endoscopic screening for synchronous esophageal neoplasia among patients with incident head and neck cancer: Prevalence, risk factors, and outcomes</p>
                          <h6>Author : Wang YK</h6>
                          <h6>Citation :  Int J Cancer. 2017 Nov 15;141(10):1987-1996</h6>
                        </div>
                        <span class="time">14.07 - 14.14</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Adjuvant chemoradiation after surgical resection in elderly patients with High-Risk Squamous Cell Carcinoma of the Head and Neck: A national cancer database analysis</p>
                          <h6>Author : Woody NM</h6>
                          <h6>Citation : Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):784-792</h6>
                        </div>
                        <span class="time">14.14 - 14.21</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Postoperative chemoradiotherapy in patients with head and neck cancer aged 70 or older with positive margins or extranodal extension and the influence of nodal classification</p>
                          <h6>Author : Emi J. Yoshida</h6>
                          <h6>Citation : Head Neck. 2018 Jun;40(6):1228-1236</h6>
                        </div>
                        <span class="time">14.21 - 14.28</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Elderly patients affected by head and neck squamous cell carcinoma unfit for standard curative treatment: Is de-intensified, hypofractionated radiotherapy a feasible strategy?</p>
                          <h6>Author : Pierluigi Bonomo</h6>
                          <h6>Citation : Oral Oncology November 2017Volume 74, Pages 142–147</h6>
                        </div>
                          <h4><span class="year">14.28 - 14.58</span>Panel Discussion on Special Population/Ederly Cancers</h4>
                      </div>
                      <!--session 4 end-->
                      <!-- session 5 start-->
                      <div class="section-tab">
                        <h3><span class="year">14.58 - 15.33</span>Session 5: Key Publications/Abstracts on HPV associated head and neck cancers</h3>
                        <span class="time">14.58 - 15.05</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i>The epidemiology of oral human papillomavirus infection in healthy populations: A systematic review and meta-analysis </p>
                          <h6>Author : Samantha Tam</h6>
                          <h6>Citation :  Oral Oncology July 2018Volume 82, Pages 91–99</h6>
                        </div>
                        <span class="time">15.05 - 15.12</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: A single-arm, phase ll study</p>
                          <h6>Author : Prof Allen M Chen </h6>
                          <h6>Citation : The lancet : Volume 18, No. 6, p803–811, June 2017</h6>
                        </div>
                        <span class="time">15.12 - 15.19</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Treatment Deintensification in Human Papillomavirus-Positive Oropharynx Cancer: Outcomes from the national cancer data base</p>
                          <h6>Author : Shayan Cheraghlou</h6>
                          <h6>Citation : Cancer. 2018 Feb 15;124(4):717-726</h6>
                        </div>
                        <span class="time">15.19 -15.26</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> The human papilloma virus: A variance in its prognostic value at different head and neck sub-sites</p>
                          <h6>Author : Hong Li</h6>
                          <h6>Citation : AHNS Annual Meeting, April 18–19, 2018</h6>
                        </div>
                        <span class="time">15.26 - 15.33</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Different clinicopathological profiles of HPV-Positive versus HPV-Negative oropharyngeal squamous cell carcinomas, with the complicating factor of smoking: The USC experience</p>
                          <h6>Author : Changxing Liu</h6>
                          <h6>Citation : AHNS Annual Meeting, April 18–19, 2018</h6>
                        </div>
                          <h4><span class="year">15.33 - 16.03</span>Panel Discussion on HPV associated head and neck cancers</h4>
                            <h4><span class="year">16.03 - 16.23</span>Tea/Coffee Break</h4>
                      </div>
                      <!--session 5 end-->
                      <!-- session 6 start-->
                      <div class="section-tab">
                        <h3><span class="year">16.23 - 17.12</span>Session 6 : Key Publications on Rare Head And Neck Cancers & Thyroid Cancers</h3>
                        <span class="time">16.23 - 16.30</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i>External beam radiation with or without concurrent chemotherapy in non-anaplastic thyroid cancer with unresectable or gross residual disease</p>
                          <h6>Author : T. Beckham</h6>
                          <h6>Citation :  2017 Published by Elsevier Inc, Volume 99, Issue 2, Supplement, Page E323</h6>
                        </div>
                        <span class="time">16.30 - 16.37</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Original article: Adenoid cystic carcinoma of head and neck: A single institutional analysis of 66 patients treated with multi-modality approach </p>
                          <h6>Author : Ajeet Kumar Gandhi </h6>
                          <h6>Citation : Indian Journal of Medical and Paediatric Oncology, Year 2015, Volume 36, Issue 3 [p. 166-171]</h6>
                        </div>
                        <span class="time">16.37 - 16.44</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Treatment-emergent hypertension and efficacy in the phase III study of (e7080) Lenvatinib in differentiated cancer of the thyroid (select)</p>
                          <h6>Author : Wirth L J</h6>
                          <h6>Citation : Cancer. 2018 Jun 1;124(11):2365-2372</h6>
                        </div>
                        <span class="time">16.44 - 16.51</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the national cancer database</p>
                          <h6>Author : Shayan Cheraghlou BA</h6>
                          <h6>Citation : Head Neck. 2018 Jul;40(7):1343-1355</h6>
                        </div>
                        <span class="time">16.51 - 16.58</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Adjuvant androgen deprivation therapy for high-risk androgen receptor-positive salivary duct carcinoma</p>
                          <h6>Author : W. Boxtel</h6>
                          <h6>Citation : Annals of Oncology 28 (Supplement 5): v372_v394, 2017</h6>
                        </div>
                        <span class="time">16.58 - 17.05</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck</p>
                          <h6>Author : Min Hee Hong</h6>
                          <h6>Citation : Head Neck. 2018 Jan;40(1):55-62</h6>
                        </div>
                        <span class="time">17.05 - 17.12</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Prolonged duration of response in Lenvatinib responders with thyroid cancer</p>
                          <h6>Author : Andrew G Gianoukakis</h6>
                          <h6>Citation : Endocr Relat Cancer June 1, 2018 25 699-704</h6>
                        </div>
                          <h4><span class="year">17.12 - 17.42</span>Panel discussion on Rare HN cancers & Thyroid Cancers</h4>
                      </div>
                      <!--session 6 end-->
                      <!-- session 7 start-->
                      <div class="section-tab">
                        <h3><span class="year">17.42 - 18.10</span>Session 7: Key Publications/Abstracts on Supportive Care</h3>
                        <span class="time">17.42 - 17.49</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i>Dysphagia Treatment for Patients With Head and Neck Cancer Undergoing Radiation Therapy: A Meta-analysis Review</p>
                          <h6>Author : Greco E</h6>
                          <h6>Citation :  Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):421-444</h6>
                        </div>
                        <span class="time">17.49 - 17.56</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Nutritional counseling with or without systematic use of oral nutritional supplements in head and neck cancer patients undergoing radiotherapy</p>
                          <h6>Author : Cereda E</h6>
                          <h6>Citation : Radiother Oncol. 2018 Jan;126(1):81-88</h6>
                        </div>
                        <span class="time">17.56 - 18.03</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Prognostic factors for tube feeding dependence after curative (chemo-) radiation in head and neck cancer: A systematic review of literature</p>
                          <h6>Author : Wopken K</h6>
                          <h6>Citation : Radiother Oncol. 2018 Jan;126(1):56-67.</h6>
                        </div>
                        <span class="time">18.03 - 18.10</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Eating As Treatment: A Stepped Wedge Randomized Controlled Trial to Improve Nutrition in Head and Neck Cancer Patients Undergoing Radiation Therapy </p>
                          <h6>Author : A.W. Lee. B</h6>
                          <h6>Citation : Britton© 2017 Published by Elsevier Inc, Volume 99, Issue 2, Supplement, Pages S120–S121</h6>
                        </div>
                      <h4><span class="year">18.10 - 18.40</span>Panel discussion on Supportive Care</h4>
                      </div>
                      <!--session 7 end-->

                    </div>
                    <div role="tabpanel" class="tab-pane " id="Section2">
                      <!--session 7 start-->
                      <div class="section-tab">
                        <h3><span class="year">09.00 - 09.42</span> Session 8 : Key Publications/Abstracts on complications in head and neck cancers</h3>
                        <span class="time">09.00 - 09.07</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i>Methods to reduce postoperative surgical site infections after head and neck oncology surgery</p>
                          <h6>Author : Richard B Cannon</h6>
                          <h6>Citation : Lancet : Volume 18, No. 7, e405–e413, July 2017</h6>
                        </div>
                        <span class="time">09.07 - 09.14</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Impact of early prophylactic feeding on long term tube dependency outcomes in patients with head and neck cancer</p>
                          <h6>Author : Teresa Brown</h6>
                          <h6>Citation : Oral Oncology September 2017 Volume 72, Pages 17–25</h6>
                        </div>
                        <span class="time">09.14 - 09.21</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Depression and survival in head and neck cancer patients</p>
                          <h6>Author : Katherine Rieke</h6>
                          <h6>Citation : Oral Oncology February 2017 Volume 65, Pages 76–82</h6>
                        </div>
                        <span class="time">09.21 - 09.28</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Original article: how common is hypothyroidism after external radiotherapy to neck in head and neck cancer patients? </p>
                          <h6>Author : Nirmala Srikantia</h6>
                          <h6>Citation : Indian Journal of Medical and Paediatric Oncology, Year 2011, Volume 32, Issue 3 [p. 143-148]</h6>
                        </div>
                        <span class="time">09.28 - 09.35</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Swallowing sparing IMRT vs Parotid sparing IMRT in head and neck cancer: Phase III randomized trial</p>
                          <h6>Author : M.Ashour</h6>
                          <h6>Citation : Radiotherapy and Oncology Volume 127, Supplement 1, April 2018, Pages S226-S227</h6>
                        </div>
                        <span class="time">09.35 - 09.42</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Sensorineural hearing loss in patients with head and neck cancer treated with chemoradiotherapy</p>
                          <h6>Author : P. D’urso</h6>
                          <h6>Citation : Radiotherapy and Oncology, April 2018,Volume 127,Supplement 1, Page S647</h6>
                        </div>
                          <h4><span class="year">09.42 - 10.12</span> Panel discussion on Complications in Head and Neck Cancers</h4>
                          <h4><span class="year">10.12 - 10.35</span> Tea/Coffee Break</h4>
                      </div>
                      <!--session 7 end-->
                      <!-- session 2 start-->
                      <div class="section-tab">
                        <h3><span class="year">10.35 - 11.31</span> Session 9: Key Publications Nact & Targeted therapies in head and neck cancers</h3>
                        <span class="time">10.35 - 10.42</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis</p>
                          <h6>Author : Benjamin Lacas</h6>
                          <h6>Citation : Lancet Oncol. 2017 Sep; 18(9): 1221–1237</h6>
                        </div>
                        <span class="time">10.42 - 10.49</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Once-a-week versus once-every-3-weeks Cisplatin chemoradiation for locally advanced head and neck cancer: A phase lll randomized non inferiority trial</p>
                          <h6>Author : Noronha V</h6>
                          <h6>Citation : J Clin Oncol. 2018 Apr 10;36(11):1064-1072</h6>
                        </div>
                        <span class="time">10.49 - 10.56</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> A tertiary care experience with Paclitaxel and Cetuximab as palliative chemotherapy in platinum sensitive and non-sensitive in head and neck cancers</p>
                          <h6>Author : Vanita Noronha</h6>
                          <h6>Citation : South Asian J Cancer. 2017 Jan-Mar;6(1):11-14</h6>
                        </div>
                        <span class="time">10.56 - 11.03</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Induction chemotherapy followed by Cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: Results of the GORTEC 2007-02 phase III randomized trial</p>
                          <h6>Author : Geoffrois L</h6>
                          <h6>Citation : J Clin Oncol. 2018 Jul 17</h6>
                        </div>
                        <span class="time">11.03 - 11.10</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Role of neoadjuvant chemotherapy in advanced carcinoma of the hypopharynx and larynx</p>
                          <h6>Author : Joshi P</h6>
                          <h6>Citation : South Asian J Cancer. 2017 Jan-Mar;6(1):15-19</h6>
                        </div>
                        <span class="time">11.10 - 11.17</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Original article: Sequential therapy (Triple drug-based induction chemotherapy followed by concurrent chemoradiotherapy) in locally advanced inoperable head and neck cancer patients - single institute experience</p>
                          <h6>Author : Naresh Somani</h6>
                          <h6>Citation : Indian Journal of Medical and Paediatric Oncology, Year 2011, Volume 32, Issue 2 [p. 86-91]</h6>
                        </div>
                      
                        <span class="time">11.17- 11.24</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Improved outcome by adding concurrent chemotherapy to
                            Cetuximab and radiotherapy for locally advanced head and neck carcinomas: Results of the GORTEC 2007-01 phase III randomized trial</p>
                          <h6>Author : Tao Y1</h6>
                          <h6>Citation : Clin Oncol. 2018 Jun 7</h6>
                        </div>
                        <span class="time">11.24 - 11.31</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Results of a randomized phase III study of Nimotuzumab in
                            combination with concurrent radiotherapy and Cisplatin versus radiotherapy and Cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck</p>
                          <h6>Author : Vijay Maruti Patil</h6>
                          <h6>Citation : ASCO 2018 Abstract 6000</h6>
                        </div>
                          <h4><span class="year">11.31 - 12.01</span> Panel Discussion on Targeted therapy in head and neck cancers</h4>
                      </div>
                      <!--session 2 end-->
                      <!-- session 3 start-->
                      <div class="section-tab">
                        <h3><span class="year">12.01 - 12.50</span>Session 10: Key Publications/Abstracts on immunotherapy and electrochemotherapy</h3>
                        <span class="time">12.01 - 12.08</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> 1042O – et al. Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase 2 study</p>
                          <h6>Author : Zandberg D</h6>
                        </div>
                        <span class="time">12.08 - 12.15</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Nivolumab vs Investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of checkmate 141 with analyses by tumor PD-L1 expression</p>
                          <h6>Author : Robert L.Ferris</h6>
                          <h6>Citation :  Oral Oncol. 2018 Jun;81:45-51</h6>
                        </div>
                        <span class="time">12.15 -12.22</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Estimated costs of Treatment-Related Adverse Events (TRAES) for Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the checkmate 141 trial</p>
                          <h6>Author : M. Venkatachalam</h6>
                          <h6>Citation : Annals of Oncology 28 (Supplement 5): v372_v394, 2017</h6>
                        </div>
                        <span class="time">12.22 - 12.29</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Health-Related Quality of Life (HRQOL) of Pembrolizumab (PEMBRO) vs Standard of Care (SOC) for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in Keynote-040</p>
                          <h6>Author : EZRA E.W. Cohen</h6>
                          <h6>Citation : ASCO Abstract 6013</h6>
                        </div>
                        <span class="time">12.29 - 12.36</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Nivolumab (nivo) vs Investigator’s Choice (IC) in Patients (PTS) with Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head And Neck (SCCHN): Analysis of checkmate 141 by age</p>
                          <h6>Author : Nabil F. Saba</h6>
                          <h6>Citation : ASCO Annual Meeting Abstract No: 6028</h6>
                        </div>
                        <span class="time">12.36 - 12.43</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Electrochemotherapy for mucosal head and neck Tumours: Results from a phase II clinical trial</p>
                          <h6>Author : C.C. Plaschke</h6>
                          <h6>Citation :  Radiotherapy  & Oncology Journal of the European SocieTy for Radiotherapy and Oncology Volume 122 Supplement 1 (2017)</h6>
                        </div>
                        <span class="time">12.43 - 12.50</span>
                        <div class="title-border">
                          <p><i class="fa fa-check-square-o" aria-hidden="true"></i> Interpreting indeterminate post-treatment PET/CT results in patients with head and neck squamous cell carcinoma</p>
                          <h6>Author : Mehdi Taghipour</h6>
                          <h6>Citation : American Journal of Roentgenology. 2016;206: 1093-1100. 10.2214/AJR.15.15604</h6>
                        </div>
                          <h4><span class="year">12.50 - 13.20</span> Panel discussion on immunotherapy </h4>
                          <h4><span class="year">13.20 - 13.30</span> Vote of thanks followed by Lunch </h4>
                      </div>
                      <!--session 3 end-->
                    </div>
                </div>
            </div>
        </div>
      <!--program end-->
